Skip to content

Startup & venture capital news

Biograil completes EUR 20m financing

Capital supports oral delivery of injectable medicines

By /

LinkedInX
Biograil: Biograil completes EUR 20m financing

Danish biotechnology company Biograil announced completion of a EUR 20 million financing round on 4 November 2026. The total includes an EUR 8.5 million first close disclosed in 2025, so the incremental amount added at completion was not stated. Verve Ventures, Megatrend Invest and HTGF Opportunity Fund were named among the investors, with no current lead identified. Biograil is developing an oral capsule that protects biological medicines and releases them through a mechanical delivery system in the intestine. The capital will advance clinical and manufacturing work intended to offer patients an alternative to repeated injections.

Keep reading

More Funding

All stories